Market for HIV Prevention Drugs May More Than Double, Citi Says

Even with approval approaching for a generic of the first medicine to prevent HIV, the U.S. market for similar medicines may more than double by 2030, a Citi analyst predicts.

Sales for HIV prevention drugs could increase to $5.5 billion by 2030 from a current total of $2 billion, despite the 2020 entry of a generic of Gilead Sciences Inc.’s Truvada, analyst Citi Andrew Baum wrote in a client note.